40 Million COVID-19 Vaccines Sold to Support Low-Income Countries

Pfizer and BioNTech announced on January 22, 2021, they would provide 40 million COVID-19 vaccines to COVAX at a not-for-profit price. The Comirnaty vaccine doses are expected to be delivered in the first quarter of 2021, subject to the negotiation and execution of supply agreements under the COVAX Facility structure.

As part of a broader strategy to support low and middle-income countries beyond the agreement with COVAX, Pfizer and BioNTech are committed to partnering with other global health stakeholders to provide expertise and resources to strengthen healthcare systems where greater support may be needed to deploy COVID-19 vaccines. 

"At Pfizer, we believe that every person deserves to be seen, heard, and cared for. That is why from the very beginning of our vaccine development program, Pfizer and BioNTech have been firmly committed to working toward equitable and affordable access of COVID-19 vaccines for people around the world," said Pfizer Chairman and CEO Albert Bourla in a press statement. 

"We share the mission of COVAX and are proud to work together so that developing countries have the same access as the rest of the world, which will bring us another step closer to ending this global pandemic and proving that science will win for everyone, everywhere."

The Pfizer-BioNTech Comirnaty COVID-19 Vaccine has not been approved or licensed by the U.S. Food and Drug Administration but has been authorized under an Emergency Use Authorization to prevent COVID-19 for use in individuals 16 years of age and older.